Skip to main content
NICE approves Xarelto to prevent atherothrombotic events in adults
10/21/2019

A final appraisal determination was issued by the National Institute for Health and Care Excellence approving the use of Bayer’s Xarelto, or rivaroxaban, to prevent atherothrombotic events in adults diagnosed with symptomatic peripheral artery disease or coronary artery disease. Results from the late-stage COMPASS study became the basis for the approval.

Full Story: